Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
where to buy fat dildos? - LovToyLand.com
Popular Articles

Vast Majority Won't Have Access To Antivirals In Pandemic But Generic Drugs Could Help Prevent Deaths
Almost 90 per cent of the world"s population will not have timely access to affordable supplies of vaccines and antiviral agents in the current influenza pandemic, but it is possible that inexpensive generic drugs that are readily available, even in developing countries, could save millions of lives.
diet pills
Boston Globe Examines Hospital's Attempt To Reduce Emergency Department Visits, Hospital Stays Among Elderly
Efforts by Massachusetts General Hospital to reduce health spending could be indicative of the difficulty the health industry faces in trying to reduce spending growth, the Boston Globe reports. Industry groups last week pledged to seek a 1.5% overall reduction in health care spending over the next 10 years.Massachusetts General"s program, which began in 2006, aims to reduce hospitalizations among the elderly by 15% to 20%, as well as to improve the quality of care the elderly receive. A study looking at 35 efforts to improve elderly care found that only six, including Massachusetts General"s program, saved money or covered their costs, the Globe reports. Massachusetts General"s program relies on nurses in primary care practices to be in regular contact with patients and provide assistance with nonmedical services. The program also uses electronic health records to coordinate care. The hospital spent $8 million to $9 million over the first three years of the program to provide enhanced services to patients. Hospital readmissions fell by 19%, admissions decreased by 17% and ED visits dropped by 15% between 2007 and 2008, according to preliminary research. The program saved enough by reducing hospital admissions and emergency department visits to cover its costs and also to generate savings of $7 million to $10 million. The overall cost for the program was about 5% less than for a group of other patients treated in a more traditional way.According to Harvard University health care economist David Cutler, improving care and reducing costs among the elderly is a necessary component of health reform. He said, "If we can"t do this, it doesn"t bode well for health reform." Eric Weil, a primary care physician and medical director of the program at Massachusetts General, said, "Medicare is looking for any and every way to save money," adding, "This is a population of patients who are sick and will get sicker over time. Any opportunity to demonstrate savings in this group of patients is good, and 5% is very good" (Kowalczyk, Boston Globe, 5/17).
News of the day
BioLineRx Announces Positive Preliminary Results From The Phase I/II Trial Of BL-1040
BioLineRx Ltd. (TASE:BLRX), a clinical stage drug development company, today announced positive preliminary results from the ongoing phase I/II clinical trial designed to assess the safety and feasibility of BL-1040, the first injectable device designed to address cardiac remodeling, in 20- 30 patients at several sites in Germany and Belgium. To date, 15 patients were successfully treated with BL-1040 with no complications. Moreover, six months follow up results from the first 5 patients show BL-1040"s efficacy in preventing cardiac remodeling and preserving cardiac function.
Cardiovascular

Growing Midwestern Clinical Research Organization Selects OmniComm Systems To Provide EClinical Solutions For Phase IV Studies

OmniComm Systems, Inc. (OTC Bulletin Board: OMCM), a leader in integrated electronic data capture (EDC) solutions for clinical trials announced that a growing US Clinical Research Organization (CRO) has selected OmniComm to provide eClinical solutions in connection with two of the CRO"s Phase IV studies covering approximately 27 sites and more than 700 subjects. Additional details were not disclosed. Phase IV studies take place after a drug has been approved for marketing and are designed to provide broader experience in evaluating the safety and effectiveness of the new medicine in larger numbers of patients, subpopulations of patients, and to compare and/or combine it with other available treatments. "We are pleased to have been selected by this CRO to provide eClinical solutions for these important Phase IV studies," said Cornelis F. Wit, OmniComm"s President and CEO. "We believe the broad scope of our integrated eClinical solutions, enhanced by the recent acquisition of eResearch Technology"s data capture unit, positions us well to offer a broad array of solutions, especially for CRO"s, pharmaceutical, biotech and medical device companies seeking cost-effective tools to capture and track outcomes of clinical trials conducted at multiple locations. We look forward to expanding the range of services we provide for companies seeking to increase efficiencies in their clinical activities." About OmniComm OmniComm Systems, Inc. provides customer-driven Internet solutions to pharmaceutical, biotechnology, research and medical device organizations that conduct life changing clinical trial research. OmniComm"s growing base of satisfied customers is a direct result of the company"s commitment to deliver products and services that ensure ease of use, faster study build, ease of integration and better performance. OmniComm"s client intuitive pricing model allows companies that range from small, to mid-size to large scale institutions to safely and efficiently capitalize on their clinical research investments. OmniComm Systems, Inc. has corporate headquarters in Ft. Lauderdale, Florida and offices in Bonn, Germany, Tula, Russia, California, Connecticut, Georgia, Illinois, New Jersey, New York, North Carolina and Tennessee. Safe Harbor Disclaimer Statements made by OmniComm included in this release may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements involve a number of risks and uncertainties such as the Company"s ability to obtain new contracts and accurately estimate net revenues due to uncertain regulatory guidance, variability in size, scope and duration of projects, and internal issues at the sponsoring client, integration of acquisitions, competitive factors, technological development, and market demand. As a result, actual results may differ materially from any financial outlooks stated herein. Further information on potential factors that could affect the Company"s financial results can be found in the Company"s Reports on Form 10-K and 10-Q filed with the Securities and Exchange Commission. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise. OmniComm Systems, Inc


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009